Eargo, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a EAR research report →
Price Chart
About the company
Eargo, Inc. , a medical device firm, strives to improve the quality of life for individuals experiencing hearing impairment across the United States. The company focuses on developing and distributing hearing aids, utilizing both direct-to-consumer and extensive omni-channel sales approaches.
- CEO
- William H. Brownie
- IPO
- 2020
- Employees
- 243
- HQ
- San Jose, CA, US
Get TickerSpark's AI analysis on EAR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $53.36M
- P/E
- -0.06
- PEG
- -0.00
- P/S
- 1.43
- P/B
- 0.10
- EV/EBITDA
- 0.27
- Div Yield
- 0.00%
- Gross Margin
- 38.28%
- Op Margin
- -300.04%
- Net Margin
- -422.81%
- ROE
- -185.26%
- ROIC
- -104.01%
Latest fiscal year · YoY change
- Revenue
- $37.25M+16.0%
- Gross Profit
- $14.26M+242.3%
- Op Income
- $-111,759,000
- Net Income
- $-157,487,000+0.2%
- EPS
- $-39.68+51.1%
- OCF Growth
- -19.1%
- FCF Growth
- -16.7%
- 52W High
- $8.48
- 52W Low
- $1.47
- 50D MA
- $2.62
- 200D MA
- $3.29
- Beta
- 1.48
- RSI (14)
- 41
- Avg Volume
- 26.89K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Eargo’s Q1 showed stronger revenue and margins, driven by Victra retail growth and better cost control, while management said cash burn should improve modestly through 2023.· May 11, 2023
- Net revenue was $11.8 million, up about 29% year over year, with gross systems shipped up about 51% to 8,705.
- Victra drove most of the growth: Eargo said all 1,500 Victra stores now carry inventory, and the channel contributed about 22% of Q1 revenue.
- Non-GAAP gross margin improved to 43.8% from 40.5% a year ago, while the non-GAAP net operating loss narrowed to $19.4 million from $27.4 million.
- Sales return rate rose to 37.4%, but management called the increase temporary and said return-reduction initiatives are being rolled out in retail.
- Cash and cash equivalents were $79.8 million at March 31, 2023, and management expects modest sequential improvement in net operating cash burn for the rest of 2023.
First quarter net revenue was $11.8 million, up approximately 29% year over year and slightly down sequentially. Gross systems shipped were 8,705, up approximately 51% year over year and roughly flat sequentially. Non-GAAP gross margin was 43.8% versus 40.5% in Q1 2022. The first quarter sales return rate was 37.4%, up 3.5 percentage points year over year and 2.5 points sequentially. Non-GAAP sales and marketing expense was $12.5 million, R&D was $3.9 million, G&A was $8.1 million, and non-GAAP net operating loss was $19.4 million versus $27.4 million a year ago. Cash and cash equivalents were $79.8 million at March 31, 2023, down from $101.2 million at December 31, 2022, and net operating cash burn was approximately $21.5 million. Management did not provide additional financial guidance, but said it expects modest sequential improvement in net operating cash burn in the remaining quarters of 2023.
Christian Gormsen framed the quarter as evidence that Eargo is progressing toward a true omnichannel model, with retail leading growth and direct-to-consumer becoming more efficient. He emphasized early success with Victra, broader availability of Eargo 7, and positive customer feedback on the device’s self-fit and reduced connectivity complaints. His tone was optimistic but still cautious, repeatedly saying the business is still early in the transition and that there is more work to do.
Adam Laponis focused on the math behind the quarter: higher shipments, better gross margin, lower operating expenses, and a smaller loss. He highlighted the 43.8% non-GAAP gross margin, the $19.4 million non-GAAP operating loss, and the $79.8 million cash balance, while noting that $21.5 million of net operating cash burn in Q1 should improve modestly sequentially through 2023. He also cautioned that Victra order timing and size may remain lumpy and affect sequential comparability, and said higher return rates should ease over time as retail initiatives mature.
Analysts focused mainly on Victra: management said every one of the 1,500 stores now has Eargo inventory, that initial stocking is basically complete, and that sell-through is improving even though sell-in still exceeded sell-through in Q1. On returns, Adam said the company previously cut return rates by about 10 points over four quarters in DTC and expects a similar, quarter-by-quarter improvement in retail, helped by training and education. On DTC, management said the business was roughly flat to slightly down year over year, but there is cross-pollination between retail and DTC leads that they expect to grow over time.
The call suggested Eargo is seeing real traction from a new retail distribution model, with Victra already contributing a meaningful share of revenue and all stores now stocked. Management also pointed to improving gross margin, lower operating expenses, and a pathway to modestly better cash burn, while Eargo 7 is getting positive customer feedback across channels.
The main risks are that Victra orders are lumpy, sell-in still outpaced sell-through, and the higher return rate may take several quarters to normalize. Direct-to-consumer growth was described as roughly flat to slightly down year over year, and management expects insurance volumes to remain low for now, so broader growth still depends on retail execution and continued improvement in customer acquisition efficiency.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 94.6%
- Shares Outstanding
- 20.76M
- Float Shares
- 19.64M
of shares held by institutions
1 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Parametric Portfolio Associates LLC | 63.97K | ▲ 24.61K |
| Gofen & Glossberg LLC | 33.06K | ▲ 15.80K |
| Maveron General Partner Iv LLC | 10.12K | 0 |
| Amalgamated Financial Corp. | 4.91K | ▲ 4.91K |
| American Portfolios Advisors | 350 | ▼ 200 |
Held by 1 ETFs
Biggest fund positions in EAR by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 16, 24 | Brownie William | sell | 38 |
| Feb 16, 24 | Brownie William | sell | 258 |
| Feb 16, 24 | Brownie William | sell | 2,206 |
| Feb 16, 24 | Narula Onkarr | sell | 5,000 |
| Feb 16, 24 | Wu David James | sell | 25,463 |
| Feb 16, 24 | Wu David James | sell | 5,000 |
| Feb 16, 24 | Sabet-Peyman Afshin Justin | sell | 5,000 |
| Feb 16, 24 | BAYNE KATIE J | sell | 5,000 |
| Feb 16, 24 | Spence Donald J | sell | 5,000 |
| Feb 16, 24 | Thorpe Mark | sell | 101 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our EAR coverage
Recent articles, reports, and earnings notes.
No research on EAR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate EAR report →Verici Dx Announces Publication Validating Pre-Transplant Gene Signature Test for Predicting Early Acute Rejection in Kidney Transplant Recipients
gurufocus.com · May 19
Eargo Debuts Two New Devices, Expanding Portfolio of Hearing Wellness Offerings
globenewswire.com · Jan 31
EARGO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Eargo, Inc. - EAR
businesswire.com · Jan 16
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation into Eargo, Inc.
prnewswire.com · Dec 19
Wolf Popper LLP Investigates the Acquisition of Eargo, Inc. by Its Controlling Shareholder, Patient Square Capital
accesswire.com · Dec 12
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eargo, Inc. and Encourages Investors to Contact the Firm
accesswire.com · Nov 3
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eargo, Inc. and Encourages Investors to Contact the Firm
accesswire.com · Nov 2
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Eargo, Inc. and Encourages Investors to Contact the Firm
accesswire.com · Nov 2
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.